Furthermore, we confirmed that PFK-015 and sunitinib could highly synergistically suppress pRCC cell proliferation, which may provide a promising new treatment strategy for advanced renal cell carcinoma making this combination drug therapy. The gene discussed is PRCC; the disease is renal cell carcinoma.